Q1 2025 revenue reached $364.5 million, at the high end of guidance, with adjusted EPS of $0.23, surpassing expectations; GAAP EPS was $2.14 due to a $176 million gain from the sale of Mably.
Significant growth was seen in Latin America (144% YoY), while U.S. and Canada faced macroeconomic headwinds; improving trends noted in South Korea, China, Europe, and Africa.
The company is launching Prism IO, an intelligent wellness platform leveraging AI and a proprietary antioxidant database, with limited rollout in Q3/Q4 2025 and broader launches in 2026; expects this to drive higher supplement sales and customer retention.
Operational improvements included reducing debt by $155 million (to $239 million), increasing cash to $204 million, and lowering G&A expenses; adjusted operating margin improved to 6.4% from 3.8% YoY.
Q2 2025 guidance: revenue between $355 million and $390 million (2-3% FX headwind expected), with reported EPS of $0.20 to $0.30; company will update guidance after Q2 as visibility improves.